SOSV secures SOSV V fund, at $306million, the firm’s largest fund to date. It will focus on deep tech startups in human and planetary health, with an emphasis on the intertwined imperatives of decarbonization and re-industrialization—part of the fund’s mandate to “reinvent the means of production”—even as SOSV continues to pioneer investments in health ranging from therapeutics to medical devices.
Sean O’Sullivan, SOSV’s founding and managing general partner said, “As the first check in deep tech, SOSV represents the start of the journey for hundreds of deep tech founders, We appreciate the dedication of many of the world’s leading family offices and corporations in backing SOSV V, enabling the creation of the most transformational climate change and human health startups on the planet. And, by partnering with later stage funds, every $100 million that we invest brings another $2 billion in follow-on capital into these companies. This new fund will enable an enormous amount of positive change for humanity.”
It invests starting at pre-seed, when companies join its HAX and IndieBio development programs, and continues through series seed, A, and later stages, resulting in about 200 investments per year. It operates startup program facilities in New York City, Newark, and San Francisco and graduates about 80 startups a year.
It tracks top portfolio startups in its annual Climate Tech 100 and Human Health 100 lists, which include standout climate companies such as NotCo (AI platform to design plant-based foods); Prolific Machines (optogenetic biomanufacturing); Unspun (3D weaving technology to decarbonize fashion); Neptune Robotics (hull-cleaning robots to reduce maritime emissions); and Zymochem (bio-based materials to decarbonize everyday products), and health companies such as Ten63 (AI and physics-driven drug discovery platform); Prellis (3D-printed lymph nodes for drug discovery); and Flow Neuroscience (depression-treating headset).
Read also – CA-based Anrok Secures $30Million in Series B Round Funding
The limited partners in SOSV V include corporates, sovereign wealth funds, institutional investors, and private family offices around the world. SOSV’s HAX and IndieBio programs are widely recognized for launching startups that are primed for institutional, early stage investors. Active deep tech co-investors in SOSV portfolio companies welcomed the SOSV V news.
Matt Ocko and Zachary Bogue, DCVC co-founders and managing partners said, “The fight against climate-driven privation, societal disruption, and loss of life is an existential fight to preserve resilience and defend abundance for all, We partner with SOSV in their Decarbonization Consortium not only because they are fellow deep-tech investors, but also because they are determined like us to find every possible way to decarbonize without deprivation. SOSV V will bring power and expertise to this fight.”
Alex Morgan, partner at Khosla Ventures said, “At Khosla Ventures, we often begin our work at Seed and Series A, partnering with great teams trying to solve big, important problems with unique, transformative technologies, We really enjoy working with SOSV, including their HAX and IndieBio programs, and we’re pleased that SOSV has closed its Fund V. We have joined together to support several exciting companies addressing human health, climate, and food—including Opentrons, Flow Neuroscience, Prellis, Oobli, and Vertical Oceans—and expect to work on more in the future.”
About SOSV
Global venture funding company SOSV runs development programmes for early-stage startups. Programmes at SOSV are centred on cutting-edge deep technology that has promise for improving both the world and humankind.
The company’s approach is to invest in a limited number of very promising firms and leverage its highly resourced programmes to expand, gain traction, and expedite product development. Top-tier investors lead investment rounds that SOSV firms regularly raise.
